Durata Therapeutics, Inc. To Present Six Dalbavancin Posters At The 24th Annual ECCMID Meeting
Published: May 02, 2014
CHICAGO, May 2, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be presented in six posters at the 24th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which takes place in Barcelona, Spain from May 10-13, 2014.
Help employers find you! Check out all the jobs and post your resume.